应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01477 欧康维视生物-B
开市前 05-16 09:13:28
7.000
+0.020
+0.29%
最高
7.000
最低
7.000
成交量
0.00
今开
7.000
昨收
6.980
日振幅
0.00%
总市值
48.69亿
流通市值
48.69亿
总股本
6.96亿
成交额
0.00
换手率
0.00%
流通股本
6.96亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
再生元制药下跌1.22%,报972.61美元/股
金融界 · 05-15 23:34
再生元制药下跌1.22%,报972.61美元/股
欧康维视生物-B05月13日主力资金流出63万元 连续3日减仓
自选股智能写手 · 05-13 16:16
欧康维视生物-B05月13日主力资金流出63万元 连续3日减仓
溢价50%!黑石(BX.US)通过MBO将日本制药服务公司I’rom私有化
智通财经 · 05-13 16:15
溢价50%!黑石(BX.US)通过MBO将日本制药服务公司I’rom私有化
东阳光药:多元化管线布局驱动成长,商业化能力助力稳健增长
每日经济新闻 · 05-13 12:16
东阳光药:多元化管线布局驱动成长,商业化能力助力稳健增长
力生制药(002393.SZ)拟公开挂牌转让田边制药24.65%股权
智通财经 · 05-10
力生制药(002393.SZ)拟公开挂牌转让田边制药24.65%股权
力生制药最新公告:公开挂牌转让天津田边制药有限公司24.65%股权
证券之星 · 05-10
力生制药最新公告:公开挂牌转让天津田边制药有限公司24.65%股权
迦南科技:公司主要业务为制药装备,持续围绕生命大健康产业做战略布局
证券之星 · 05-10
迦南科技:公司主要业务为制药装备,持续围绕生命大健康产业做战略布局
欧康维视生物-B05月10日遭主力抛售228万元 环比增加165.12%
自选股智能写手 · 05-10
欧康维视生物-B05月10日遭主力抛售228万元 环比增加165.12%
谷歌搅局AI制药,进击的AlphaFold3模型
蓝鲸财经 · 05-10
谷歌搅局AI制药,进击的AlphaFold3模型
港股异动 | 中生制药(01177)现涨超6% 旗下肺癌药物获批上市 52项研究成果将在24年ASCO公布
智通财经 · 05-09
港股异动 | 中生制药(01177)现涨超6% 旗下肺癌药物获批上市 52项研究成果将在24年ASCO公布
中生制药(01177.HK)旗下肺癌药物获国家药监局批准上市
阿斯达克财经 · 05-09
中生制药(01177.HK)旗下肺癌药物获国家药监局批准上市
黄仁勋看好的下一个万亿美元AI赛道是什么? |【经纬低调研究】
经纬创投 · 05-09
黄仁勋看好的下一个万亿美元AI赛道是什么? |【经纬低调研究】
再生元制药下跌1.32%,报957.17美元/股
金融界 · 05-09
再生元制药下跌1.32%,报957.17美元/股
谱尼测试:湖北中佳合成制药股份有限公司是谱尼集团的全资子公司
证券之星 · 05-08
谱尼测试:湖北中佳合成制药股份有限公司是谱尼集团的全资子公司
再生元制药上涨1.21%,报970.245美元/股
金融界 · 05-08
再生元制药上涨1.21%,报970.245美元/股
再生元制药上涨1.21%,报949.0美元/股
金融界 · 05-04
再生元制药上涨1.21%,报949.0美元/股
美国制药公司安进减肥药引发关注 诺和诺德股价下跌5%
每日经济新闻 · 05-03
美国制药公司安进减肥药引发关注 诺和诺德股价下跌5%
欧康维视生物-B(01477)下跌5.1%,报7.07元/股
金融界 · 05-03
欧康维视生物-B(01477)下跌5.1%,报7.07元/股
欧康维视生物-B盘中异动 下午盘股价大跌5.09%
自选股智能写手 · 05-03
欧康维视生物-B盘中异动 下午盘股价大跌5.09%
再生元制药上涨3.02%,报930.755美元/股
金融界 · 05-02
再生元制药上涨3.02%,报930.755美元/股
暂无数据
公司概况
公司名称:
欧康维视生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401(YUTIQ)、OT-1001(ZERVIATE)、OT-502(DEXYCU)、OT-301(NCX 470)、OT-101和OT-202等。该公司在中国境内开展业务。
发行价格:
--
{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7,"timestamp":1715821247001,"preClose":6.98,"halted":0,"volume":0,"delay":0,"floatShares":695614850,"shares":695614850,"eps":-0.63351554,"marketStatus":"开市前","marketStatusCode":1,"change":0.02,"latestTime":"05-16 09:13:28","open":7,"high":7,"low":7,"amount":0,"amplitude":0,"askPrice":7,"askSize":500,"bidPrice":7,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.6335155129413969,"exchange":"SEHK","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715823000000},"adr":0,"listingDate":1594310400000,"adjPreClose":6.98,"openAndCloseTimeList":[[1715823000000,1715832000000],[1715835600000,1715846400000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477/tweets","defaultTab":"tweets","newsList":[{"id":"2435365238","title":"再生元制药下跌1.22%,报972.61美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435365238","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2435365238?lang=zh_cn&edition=full","pubTime":"2024-05-15 23:34","pubTimestamp":1715787291,"startTime":"0","endTime":"0","summary":"5月15日,再生元制药(REGN)盘中下跌1.22%,截至23:34,报972.61美元/股,成交1.86亿美元。财务数据显示,截至2024年03月31日,再生元制药收入总额31.45亿美元,同比减少0.54%;归母净利润7.22亿美元,同比减少11.71%。大事提醒:5月14日,再生元制药获Evercore ISI首次给予评级Outperform,目标价1150美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/15233440660683.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435346735","title":"欧康维视生物-B05月13日主力资金流出63万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2435346735","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435346735?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:16","pubTimestamp":1715588211,"startTime":"0","endTime":"0","summary":"05月13日, 欧康维视生物-B股价涨2.80%,报收6.98元,成交金额1552万元,换手率0.32%,振幅4.42%,量比1.15。欧康维视生物-B今日主力资金净流出63万元,连续3日净流出,上一交易日主力净流出228万元,今日环比减少72.37%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为50.00%,平均跌幅为1.88%。该股近5个交易日下跌4.52%,主力资金累计净流出944万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出1073万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051316181187613cfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051316181187613cfa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435450503","title":"溢价50%!黑石(BX.US)通过MBO将日本制药服务公司I’rom私有化","url":"https://stock-news.laohu8.com/highlight/detail?id=2435450503","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435450503?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:15","pubTimestamp":1715588115,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,黑石正与日本制药服务公司I’rom Group的管理层合作,将后者私有化。黑石将以每股2800日元的价格收购I’rom的股份,较该公司周一收盘价1873日元溢价约50%。剩下的45%股份将由I ' rom的创始人兼总裁Toyotaka Mori持有。I 'rom专门从事肿瘤药物试验,随着日本人口老龄化,这一领域的需求预计会增加。在I’rom私有化后,Mori将继续担任首席执行官。五个月前,黑石宣布将从索尼集团手中收购一家支付服务提供商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120444.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435390264","title":"东阳光药:多元化管线布局驱动成长,商业化能力助力稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2435390264","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2435390264?lang=zh_cn&edition=full","pubTime":"2024-05-13 12:16","pubTimestamp":1715573766,"startTime":"0","endTime":"0","summary":"此次入围榜单,充分体现了东阳光药在中国医药行业的领军地位。研发创新驱动成长,多元化管线布局东阳光药拥有出色的研发能力。近日,胰岛素国家续采落地,东阳光药成为本次接续采购最大的受益者之一。总体来看,凭借其强大的研发实力、多元化的产品管线、突出的商业化能力和国际化的战略布局,东阳光药不仅在国内市场取得了显","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131219328760969e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131219328760969e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434839927","title":"力生制药(002393.SZ)拟公开挂牌转让田边制药24.65%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2434839927","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434839927?lang=zh_cn&edition=full","pubTime":"2024-05-10 18:24","pubTimestamp":1715336645,"startTime":"0","endTime":"0","summary":"智通财经APP讯,力生制药(002393.SZ)公告,公司拟按照不低于1.2亿元的底价在天津产权交易中心公开挂牌转让所持天津田边制药有限公司(简称“田边制药”)24.65%股权。交易完成后,公司将不再持有田边制药的股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119898.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434383672","title":"力生制药最新公告:公开挂牌转让天津田边制药有限公司24.65%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2434383672","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434383672?lang=zh_cn&edition=full","pubTime":"2024-05-10 18:11","pubTimestamp":1715335860,"startTime":"0","endTime":"0","summary":"力生制药公告,为进一步优化资源配置,结合资产评估结果及市场情况,拟按照不低于12,029.20万元的底价公开挂牌转让所持24.65%股权。本次交易完成后,公司将不再持有田边制药的股权。根据《上市公司重大资产重组管理办法》规定,本次交易不构成重大资产重组。该事项经公司股东大会和相关主管部门批准后,在天津产权交易中心公开挂牌转让。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000036307.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434138838","title":"迦南科技:公司主要业务为制药装备,持续围绕生命大健康产业做战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2434138838","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434138838?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:01","pubTimestamp":1715331681,"startTime":"0","endTime":"0","summary":"证券之星消息,迦南科技05月10日在投资者关系平台上答复投资者关心的问题。具体产品情况请参阅公司披露的定期报告及公开信息。例如公司的生物发酵系统、配液系统、冻干系统、制剂设备系列等,均可根据客户需求提供。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000031262.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434388221","title":"欧康维视生物-B05月10日遭主力抛售228万元 环比增加165.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434388221","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2434388221?lang=zh_cn&edition=full","pubTime":"2024-05-10 16:15","pubTimestamp":1715328949,"startTime":"0","endTime":"0","summary":"05月10日, 欧康维视生物-B股价跌2.86%,报收6.79元,成交金额1148万元,换手率0.24%,振幅3.86%,量比0.94。欧康维视生物-B今日主力资金净流出228万元,上一交易日主力净流出86万元,今日环比增加165.12%。该股近5个交易日下跌5.17%,主力资金累计净流出898万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出973万元,其中净流出天数为9日。该股主力净额占比0.05%,港股市场排名2555/2622。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101616238af03184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101616238af03184&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434007272","title":"谷歌搅局AI制药,进击的AlphaFold3模型","url":"https://stock-news.laohu8.com/highlight/detail?id=2434007272","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2434007272?lang=zh_cn&edition=full","pubTime":"2024-05-10 13:53","pubTimestamp":1715320436,"startTime":"0","endTime":"0","summary":"不过,谷歌AlphaFold3模型问世,或许标志着CSP领域达到了一个新的高度。日前,Nature上发表的关于AlphaFold3模型的介绍,为我们揭示了这一点。之前的AlphaFold 模型于 2020 年发布,其预测蛋白质结构的能力让研究界感到惊讶,但研究人员一直在呼吁该工具能够处理的不仅仅是蛋白质。现在,AlphaFold 3,可以预测DNA、RNA和配体等分子的结构,这对药物发现至关重要。总体而言,AlphaFold3在多个方面展现了其卓越的性能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/231725","is_publish_highlight":false,"gpt_icon":0},{"id":"2434058990","title":"港股异动 | 中生制药(01177)现涨超6% 旗下肺癌药物获批上市 52项研究成果将在24年ASCO公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2434058990","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434058990?lang=zh_cn&edition=full","pubTime":"2024-05-09 13:36","pubTimestamp":1715232972,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中生制药现涨近6%,截至发稿,涨6.19%,报3.09港元,成交额1.59亿港元。消息面上,中国生物制药公布,集团自主研发的1类创新药贝莫苏拜单抗注射液\"Benmelstobart \"已获得中国国家药品监督管理局的上市批准,联合盐酸安罗替尼胶囊、卡铂和依托泊甘用于广泛期小细胞肺癌患者的一线治疗。据悉,这是贝莫苏拜单抗注射液在中国获批的首个适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119165.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434803264","title":"中生制药(01177.HK)旗下肺癌药物获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2434803264","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2434803264?lang=zh_cn&edition=full","pubTime":"2024-05-09 12:21","pubTimestamp":1715228460,"startTime":"0","endTime":"0","summary":"中国生物制药公布,其自主研发的1类创新药贝莫苏拜单抗注射液“Benmelstobart”已获得中国国家药品监督管理局的上市批准,联合盐酸安罗替尼胶囊、卡铂和依托泊甘用于广泛期小细胞肺癌患者的一线治疗。此前,盐酸安罗替尼胶囊已获批5个适应症,包括三线非小细胞肺癌、三线小细胞肺癌、软组织肉瘤、甲状腺髓样癌和分化型甲状腺癌。(港股报价延迟最少十五分钟。沽空资料截至 2024-05-08 16:25。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1348440/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2434817037","title":"黄仁勋看好的下一个万亿美元AI赛道是什么? |【经纬低调研究】","url":"https://stock-news.laohu8.com/highlight/detail?id=2434817037","media":"经纬创投","top":-1,"share":"https://www.laohu8.com/m/news/2434817037?lang=zh_cn&edition=full","pubTime":"2024-05-09 12:03","pubTimestamp":1715227380,"startTime":"0","endTime":"0","summary":"如果要问AI的下一个黄金赛道是什么?黄仁勋的答案是生命科学。不仅仅是黄仁勋这么说,英伟达对外投资也证明了这一点。她说,这种合作关系最终促成了投资,英伟达还帮助公司解决了有关手术机器人的技术监管担忧。这个复合体参与了其他蛋白质的生成,这是一个对生命和健康至关重要的细胞过程。1AI在制药方面到底能做什么?实验证明,有些药物不能杀死保罗的癌细胞,有些药物反而损害了他的健康细胞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962174560&idx=1&sn=6561a99e23208c6a65990b4fb7496177&chksm=ab7633b719babb5378370ae9a35c52a5b86b646e078f4926c27ec3cda1ce042d9766ad6f4462&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2434797697","title":"再生元制药下跌1.32%,报957.17美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2434797697","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434797697?lang=zh_cn&edition=full","pubTime":"2024-05-09 01:04","pubTimestamp":1715187880,"startTime":"0","endTime":"0","summary":"5月9日,再生元制药(REGN)盘中下跌1.32%,截至01:04,报957.17美元/股,成交1.61亿美元。财务数据显示,截至2024年03月31日,再生元制药收入总额31.45亿美元,同比减少0.54%;归母净利润7.22亿美元,同比减少11.71%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/09010440572317.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433740518","title":"谱尼测试:湖北中佳合成制药股份有限公司是谱尼集团的全资子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2433740518","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433740518?lang=zh_cn&edition=full","pubTime":"2024-05-08 20:00","pubTimestamp":1715169631,"startTime":"0","endTime":"0","summary":"证券之星消息,谱尼测试05月08日在投资者关系平台上答复投资者关心的问题。目前未开展生物合成业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800036621.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433734539","title":"再生元制药上涨1.21%,报970.245美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433734539","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433734539?lang=zh_cn&edition=full","pubTime":"2024-05-08 03:59","pubTimestamp":1715111995,"startTime":"0","endTime":"0","summary":"5月8日,再生元制药(REGN)盘中上涨1.21%,截至03:59,报970.245美元/股,成交2.74亿美元。财务数据显示,截至2024年03月31日,再生元制药收入总额31.45亿美元,同比减少0.54%;归母净利润7.22亿美元,同比减少11.71%。大事提醒:5月3日,再生元制药获Cantor Fitzgerald重申评级Neutral,目标价上调至925美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/08035940555845.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432823184","title":"再生元制药上涨1.21%,报949.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432823184","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432823184?lang=zh_cn&edition=full","pubTime":"2024-05-04 01:49","pubTimestamp":1714758540,"startTime":"0","endTime":"0","summary":"5月4日,再生元制药(REGN)盘中上涨1.21%,截至01:49,报949.0美元/股,成交1.87亿美元。财务数据显示,截至2024年03月31日,再生元制药收入总额31.45亿美元,同比减少0.54%;归母净利润7.22亿美元,同比减少11.71%。大事提醒:5月2日,再生元制药2024年一季度累计回购金额2.913亿美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/04014940516678.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432295669","title":"美国制药公司安进减肥药引发关注 诺和诺德股价下跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432295669","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2432295669?lang=zh_cn&edition=full","pubTime":"2024-05-03 17:32","pubTimestamp":1714728752,"startTime":"0","endTime":"0","summary":"美国制药公司安进减肥药引发关注 诺和诺德股价下跌5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202405033066339130.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202405033066339130.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432943745","title":"欧康维视生物-B(01477)下跌5.1%,报7.07元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432943745","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432943745?lang=zh_cn&edition=full","pubTime":"2024-05-03 14:32","pubTimestamp":1714717960,"startTime":"0","endTime":"0","summary":"5月3日,欧康维视生物-B(01477)盘中下跌5.1%,截至14:32,报7.07元/股,成交364.49万元。欧康维视生物是一家专注于眼科医药领域的公司,主要业务包括识别、开发和商业化眼科疗法。公司自成立以来,一直致力于构建整合研发、制造到商业化的眼科药物开发全周期专业能力,以满足中国眼科医疗的巨大需求缺口。截至2023年年报,欧康维视生物-B营业总收入2.46亿元、净利润-3.8亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/03143240514213.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432438979","title":"欧康维视生物-B盘中异动 下午盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432438979","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432438979?lang=zh_cn&edition=full","pubTime":"2024-05-03 14:21","pubTimestamp":1714717313,"startTime":"0","endTime":"0","summary":"2024年05月03日下午盘14时21分,欧康维视生物-B股票出现异动,股价快速跳水5.09%。截至发稿,该股报7.071港元/股,成交量42.2万股,换手率0.06%,振幅6.31%。欧康维视生物-B股票所在的生物技术行业中,整体跌幅为0.95%。欧康维视生物-B公司简介:欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503142153861eacbe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503142153861eacbe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432398136","title":"再生元制药上涨3.02%,报930.755美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432398136","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432398136?lang=zh_cn&edition=full","pubTime":"2024-05-02 23:46","pubTimestamp":1714664761,"startTime":"0","endTime":"0","summary":"5月2日,再生元制药(REGN)盘中上涨3.02%,截至23:46,报930.755美元/股,成交3.28亿美元。财务数据显示,截至2024年03月31日,再生元制药收入总额31.45亿美元,同比减少0.54%;归母净利润7.22亿美元,同比减少11.71%。大事提醒:5月2日,再生元制药2024年一季度累计回购金额2.913亿美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/02234640511904.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0425},{"period":"1month","weight":0.1851},{"period":"3month","weight":0.4542},{"period":"6month","weight":-0.0555},{"period":"1year","weight":-0.134},{"period":"ytd","weight":0.0449}],"compareEarnings":[{"period":"1week","weight":0.0322},{"period":"1month","weight":0.1407},{"period":"3month","weight":0.2012},{"period":"6month","weight":0.0696},{"period":"1year","weight":-0.0449},{"period":"ytd","weight":0.1189}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401(YUTIQ)、OT-1001(ZERVIATE)、OT-502(DEXYCU)、OT-301(NCX 470)、OT-101和OT-202等。该公司在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.137321},{"month":2,"riseRate":0.25,"avgChangeRate":-0.072355},{"month":3,"riseRate":0.5,"avgChangeRate":0.043389},{"month":4,"riseRate":0.25,"avgChangeRate":0.004659},{"month":5,"riseRate":0.5,"avgChangeRate":0.074988},{"month":6,"riseRate":0.666667,"avgChangeRate":0.085171},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.038817},{"month":8,"riseRate":0.5,"avgChangeRate":-0.01818},{"month":9,"riseRate":0,"avgChangeRate":-0.13975},{"month":10,"riseRate":0.25,"avgChangeRate":-0.152265},{"month":11,"riseRate":0.5,"avgChangeRate":0.029996},{"month":12,"riseRate":0.75,"avgChangeRate":0.144341}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}